- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Marksans Pharma arm gets marketing authorisation for Cyanocobalamin 50mg film coated tablets from UK MHRA
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.Medical Dialogues team had earlier reported that the Company had received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium...
Mumbai: Marksans Pharma Limited has announced that its wholly owned subsidiary Relonchem Limited has received Marketing Authorisation for the product Cyanocobalamin 50mg film coated tablets from UK MHRA.
Medical Dialogues team had earlier reported that the Company had received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC).
Read also: Marksans Pharma bags USFDA nod for Esomeprazole Magnesium Delayed Release Capsules
Marksans Pharma Limited headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.
Read also: Marksans Pharma Mucus loosening drug Guaifenesin ER bags USFDA okay
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751